• Summit Therapeutics Co-Chief Executive Officer Mahkam Zanganeh reported a purchase of 3.81 million common shares at USD 13.12.
• The shares were reported as indirectly owned through her spouse.
• Indirect holdings were reported through family trusts, including 25,824,474 shares in a revocable trust and 10,199,776 shares in an irrevocable trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001507650-26-000007), on June 12, 2026, and is solely responsible for the information contained therein.